In the additional CRC patients cohort, we found that after Bev treatment, the serum CCL24 (sCCL24) concentration in patients was significantly upregulated and serological CCL24 content in patients resistant to Bev treatment was increased. Here, CCL24 is linked to colorectal carcinoma.